000739 普洛药业
已收盘 12-17 15:00:00
资讯
新帖
简况
普洛药业（000739）披露取得食品生产许可证，12月11日股价下跌0.12%
证券之星 · 12-11
普洛药业（000739）披露取得食品生产许可证，12月11日股价下跌0.12%
普洛药业（000739）披露实施2025年第二次回购公司股份方案之首次回购股份暨进展公告，12月01日股价上涨1.12%
证券之星 · 12-01
普洛药业（000739）披露实施2025年第二次回购公司股份方案之首次回购股份暨进展公告，12月01日股价上涨1.12%
普洛药业(000739.SZ)：阿莫西林克拉维酸钾片获得药品注册证书
智通财经 · 12-01
普洛药业(000739.SZ)：阿莫西林克拉维酸钾片获得药品注册证书
普洛药业：医美化妆品原料业务正处开发阶段
证券之星 · 11-25
普洛药业：医美化妆品原料业务正处开发阶段
普洛药业：丁二磺酸腺苷蛋氨酸肠溶片已中标两大联盟
证券之星 · 11-25
普洛药业：丁二磺酸腺苷蛋氨酸肠溶片已中标两大联盟
普洛药业（000739）披露获得药品注册证书，11月24日股价下跌0.06%
证券之星 · 11-24
普洛药业（000739）披露获得药品注册证书，11月24日股价下跌0.06%
普洛药业(000739.SZ)子公司取得头孢地尼干混悬剂药品注册证书
智通财经 · 11-24
普洛药业(000739.SZ)子公司取得头孢地尼干混悬剂药品注册证书
普洛药业（000739）披露2025年第二次回购股份计划，11月21日股价上涨1.41%
证券之星 · 11-21
普洛药业（000739）披露2025年第二次回购股份计划，11月21日股价上涨1.41%
普洛药业（000739）披露获得药品注册证书，11月20日股价上涨2.16%
证券之星 · 11-20
普洛药业（000739）披露获得药品注册证书，11月20日股价上涨2.16%
普洛药业(000739.SZ)头孢地尼胶囊获药品注册证书
智通财经 · 11-20
普洛药业(000739.SZ)头孢地尼胶囊获药品注册证书
普洛药业(000739.SZ)拟斥资1.8亿元至3.6亿元实施回购
智通财经 · 11-19
普洛药业(000739.SZ)拟斥资1.8亿元至3.6亿元实施回购
普洛药业（000739）披露获得药品注册证书，11月14日股价上涨0.96%
证券之星 · 11-14
普洛药业（000739）披露获得药品注册证书，11月14日股价上涨0.96%
普洛药业(000739.SZ)：注射用盐酸地尔硫䓬获得药品注册证书
智通财经 · 11-14
普洛药业(000739.SZ)：注射用盐酸地尔硫䓬获得药品注册证书
普洛药业（000739）披露股份回购完成暨股份变动的公告，11月13日股价上涨0.78%
证券之星 · 11-13
普洛药业（000739）披露股份回购完成暨股份变动的公告，11月13日股价上涨0.78%
普洛药业(000739.SZ)：盐酸文拉法辛获得化学原料药欧洲CEP证书
智通财经 · 11-10
普洛药业(000739.SZ)：盐酸文拉法辛获得化学原料药欧洲CEP证书
普洛药业（000739）披露签署战略合作框架协议，11月06日股价上涨0.33%
证券之星 · 11-06
普洛药业（000739）披露签署战略合作框架协议，11月06日股价上涨0.33%
普洛药业最新公告：与嘉兴安帝康生物科技签署战略合作框架协议
证券之星 · 11-06
普洛药业最新公告：与嘉兴安帝康生物科技签署战略合作框架协议
普洛药业：公司会在回购期限内如期完成本次回购
证券之星 · 11-04
普洛药业：公司会在回购期限内如期完成本次回购
普洛药业：公司拥有奥司他韦、金刚烷胺、头孢系列等多种可用于治疗流感的药品
证券之星 · 11-04
普洛药业：公司拥有奥司他韦、金刚烷胺、头孢系列等多种可用于治疗流感的药品
普洛药业(000739.SZ)累计回购1006万股 耗资1.44亿元
智通财经网 · 11-03
普洛药业(000739.SZ)累计回购1006万股 耗资1.44亿元
加载更多
公司概况
公司名称：
普洛药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-09
主营业务：
普洛药业股份有限公司的主营业务是原料药中间体、创新药研发生产服务（CDMO）、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是头孢系列、青霉素系列、精神类系列、心脑血管类系列、兽药原料药中间体系列、研发服务、商业化人用药项目、商业化兽药项目、其他项目、抗感染类、心脑血管类、精神类、抗肿瘤类。
发行价格：
5.70
{"stockData":{"symbol":"000739","market":"SZ","secType":"STK","nameCN":"普洛药业","latestPrice":16.35,"timestamp":1765955028000,"preClose":16.06,"halted":0,"volume":6232167,"delay":0,"changeRate":0.0181,"floatShares":1158000000,"shares":1158000000,"eps":0.7439,"marketStatus":"已收盘","change":0.29,"latestTime":"12-17 15:00:00","open":16.04,"high":16.35,"low":16.04,"amount":101000000,"amplitude":0.0193,"askPrice":16.35,"askSize":745,"bidPrice":16.34,"bidSize":123,"shortable":0,"etf":0,"ttmEps":0.7439,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.06,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":17.67,"lowLimit":14.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1158443576,"isCdr":false,"pbRate":2.87,"roa":"--","peRate":21.978761,"roe":"10.21%","epsLYR":0.8864,"committee":-0.630856,"marketValue":18941000000,"turnoverRate":0.0054,"status":0,"floatMarketCap":18933000000},"requestUrl":"/m/hq/s/000739","defaultTab":"news","newsList":[{"id":"2590514387","title":"普洛药业（000739）披露取得食品生产许可证，12月11日股价下跌0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590514387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590514387?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:20","pubTimestamp":1765462826,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，普洛药业报收于16.08元，较前一交易日下跌0.12%，最新总市值为186.28亿元。近日，普洛药业股份有限公司全资子公司浙江普洛生物科技有限公司收到浙江省市场监督管理局颁发的蝙蝠蛾被毛孢菌丝体粉的《食品生产许可证》。此次获证标志着公司具备相关品种生产资质，有助于开展保健食品生产经营活动，提升可持续生产能力，对公司拓展保健食品业务具有积极意义。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0188","BK0239"],"gpt_icon":0},{"id":"2588725642","title":"普洛药业（000739）披露实施2025年第二次回购公司股份方案之首次回购股份暨进展公告，12月01日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725642","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725642?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:53","pubTimestamp":1764582800,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，普洛药业报收于16.18元，较前一交易日上涨1.12%，最新总市值为187.44亿元。公司近日发布公告称，普洛药业于2025年11月28日首次通过集中竞价方式回购股份230,000股，占公司总股本的0.02%，最高成交价16.00元/股，最低成交价15.91元/股，成交总金额3,669,192元。本次回购资金总额不低于18,000万元且不超过36,000万元，回购股份拟用于股权激励或员工持股计划，回购期限为自董事会审议通过之日起12个月内。本次回购符合相关法规及公司回购方案要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","000739","BK0239"],"gpt_icon":0},{"id":"2588728964","title":"普洛药业(000739.SZ)：阿莫西林克拉维酸钾片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728964","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588728964?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:01","pubTimestamp":1764579670,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司全资子公司浙江普洛巨泰药业有限公司收到国家药品监督管理局(以下简称“药监局”)签发的阿莫西林克拉维酸钾片《药品注册证书》。本品用于治疗以下感染:上呼吸道感染(包括耳、鼻、喉科)：复发性扁桃体炎、鼻窦炎、中耳炎。下呼吸道感染：急、慢性支气管炎(尤适用于严重感染)、大叶性肺炎、支气管肺炎。泌尿系统感染：膀胱炎(特别是感染反复发作或复杂感染,不包括前列腺炎)。皮肤和软组织感染：如蜂窝组织炎、动物咬伤合并伤口感染。口腔感染：严重的齿龈脓肿合并颌面部蜂窝组织炎。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0060","000739","BK0239"],"gpt_icon":0},{"id":"2586411445","title":"普洛药业：医美化妆品原料业务正处开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2586411445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586411445?lang=zh_cn&edition=full","pubTime":"2025-11-25 08:46","pubTimestamp":1764031572,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：2024年11月4日，普洛药业正式成立医美及化妆品事业部，并以“助力美好生活”为使命，请问成立一年来医美事业部发展如何？开发了哪些产品和客户？事业部人员和市场开拓规模怎么样？普洛药业回复：投资者您好！医美化妆品原料业务是公司重点培育的发展方向，目前正处于新产品和新客户开发阶段，预计未来几年该业务市场规模有望实现较快的增长。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500004463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000739","BK0060"],"gpt_icon":0},{"id":"2586411303","title":"普洛药业：丁二磺酸腺苷蛋氨酸肠溶片已中标两大联盟","url":"https://stock-news.laohu8.com/highlight/detail?id=2586411303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586411303?lang=zh_cn&edition=full","pubTime":"2025-11-25 08:30","pubTimestamp":1764030627,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司丁二磺酸苷蛋氨酸肠溶片，因为是天然生理活性分子，药理作用机制明确，安全性高，临床疗效好，作为值得推广的首选肝病治疗药物，获批上市一年多，市场推广和销售情况如何？普洛药业回复：投资者您好！公司丁二磺酸腺苷蛋氨酸肠溶片于2024年11月获批，目前在京津冀“3+N”联盟和广东联盟中已中标，正处于快速拓展市场中。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500004260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","000739","BK0239"],"gpt_icon":0},{"id":"2585949884","title":"普洛药业（000739）披露获得药品注册证书，11月24日股价下跌0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585949884","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585949884?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:22","pubTimestamp":1763994172,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，普洛药业报收于15.83元，较前一交易日下跌0.06%，最新总市值为183.38亿元。该股当日开盘15.9元，最高16.07元，最低15.73元，成交额达1.54亿元，换手率为0.84%。公司近日发布公告称，其全资子公司浙江普洛巨泰药业有限公司收到国家药品监督管理局签发的头孢地尼干混悬剂药品注册证书，批准注册并发放证书。该产品属第三代口服头孢菌素类抗生素，适用于儿童轻度至中度感染治疗。截至公告日，该项目累计研发投入1024.27万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000739","BK0188"],"gpt_icon":0},{"id":"2585454824","title":"普洛药业(000739.SZ)子公司取得头孢地尼干混悬剂药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585454824","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585454824?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:59","pubTimestamp":1763971188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)公告，公司全资子公司浙江普洛巨泰药业有限公司收到国家药品监督管理局签发的头孢地尼干混悬剂(1.5g;3.0g)《药品注册证书》。公告显示，头孢地尼干混悬剂，属于第三代口服头孢菌素类抗生素，适用于治疗由下列条件下的指定微生物的敏感菌株引起的轻度至中度感染的儿童患者。急性细菌性中耳炎由流感嗜血杆菌(包括产生β-内酰胺酶的菌株)、肺炎链球菌(仅对青霉素敏感的菌株)和卡他莫拉菌(包括产生β-内酰胺酶的菌株)引起。咽炎/扁桃体炎由化脓性链球菌引起。单纯性皮肤和皮肤组织感染由金黄色葡萄球菌(包括产生β-内酰胺酶的菌株)和化脓性链球菌引起。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)子公司取得头孢地尼干混悬剂药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0188","BK0239","000739"],"gpt_icon":0},{"id":"2585995149","title":"普洛药业（000739）披露2025年第二次回购股份计划，11月21日股价上涨1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585995149","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585995149?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:32","pubTimestamp":1763735552,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，普洛药业报收于15.84元，较前一交易日上涨1.41%，最新总市值为183.5亿元。该股当日开盘15.65元，最高15.98元，最低15.6元，成交额达2.71亿元，换手率为1.47%。公司近日发布公告称，普洛药业股份有限公司于2025年11月18日召开第九届董事会第十七次会议，审议通过《关于2025年第二次回购公司股份方案的议案》。回购股份将用于股权激励或员工持股计划。公司已开立回购专用证券账户，截至公告日持股5%以上股东无减持计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0239","000739"],"gpt_icon":0},{"id":"2584192130","title":"普洛药业（000739）披露获得药品注册证书，11月20日股价上涨2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584192130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584192130?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:26","pubTimestamp":1763648784,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，普洛药业报收于15.62元，较前一交易日上涨2.16%，最新总市值为180.95亿元。该股当日开盘15.51元，最高15.86元，最低15.51元，成交额达1.6亿元，换手率为0.88%。近日，普洛药业发布公告称，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的头孢地尼胶囊《药品注册证书》。头孢地尼胶囊适用于多种细菌引起的感染，2024年中国院内市场规模为3.8亿粒，销售金额3.1亿元。截至公告日，该项目累计研发投入528.18万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","000739","BK0239"],"gpt_icon":0},{"id":"2584189583","title":"普洛药业(000739.SZ)头孢地尼胶囊获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2584189583","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584189583?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:25","pubTimestamp":1763627118,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业 公告，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的头孢地尼胶囊《药品注册证书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)头孢地尼胶囊获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","000739","BK0188"],"gpt_icon":0},{"id":"2584563919","title":"普洛药业(000739.SZ)拟斥资1.8亿元至3.6亿元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2584563919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584563919?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:43","pubTimestamp":1763541783,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)披露025年第二次回购公司股份方案，公司回购股份拟用于股权激励或员工持股计划，本次回购资金总额不低于人民币1.8亿元(含)且不超过人民币3.6亿元(含)。本次回购股份价格不超过人民币23元/股(含)。回购期限自公司董事会审议通过本次回购股份方案之日起12个月内。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000739","BK0239","BK0060"],"gpt_icon":0},{"id":"2583507659","title":"普洛药业（000739）披露获得药品注册证书，11月14日股价上涨0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507659","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583507659?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:59","pubTimestamp":1763132359,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，普洛药业报收于15.73元，较前一交易日上涨0.96%，最新总市值为182.22亿元。该股当日开盘15.53元，最高15.87元，最低15.51元，成交额达1.33亿元，换手率为0.73%。近日，普洛药业发布公告称，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的注射用盐酸地尔硫《药品注册证书》。此次获批有利于公司参与国家药品集采，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0060","BK0188","BK0239"],"gpt_icon":0},{"id":"2583571817","title":"普洛药业(000739.SZ)：注射用盐酸地尔硫䓬获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583571817","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583571817?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:33","pubTimestamp":1763112792,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 普洛药业 发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的注射用盐酸地尔硫《药品注册证书》。根据相关数据显示，注射用盐酸地尔硫2024年度中国院内市场规模为400万支，销售金额为1.4亿元。本次注射用盐酸地尔硫获得药品注册证书，视同通过仿制药质量和疗效一致性评价，将具备后续参加国家药品集中采购的资格，有利于扩大该产品的市场销售，提高市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000739","BK0239","BK0060"],"gpt_icon":0},{"id":"2583964235","title":"普洛药业（000739）披露股份回购完成暨股份变动的公告，11月13日股价上涨0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583964235","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583964235?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:22","pubTimestamp":1763043744,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，普洛药业报收于15.58元，较前一交易日上涨0.78%，最新总市值为180.49亿元。该股当日开盘15.46元，最高15.62元，最低15.41元，成交额达9594.41万元，换手率为0.53%。公司近日发布公告称，普洛药业于2025年2月19日审议通过股份回购方案，拟使用自有资金及金融机构借款以集中竞价方式回购股份，用于股权激励或员工持股计划。回购股份存放于专用账户，后续将用于股权激励或员工持股计划，若未在36个月内实施，未使用部分将注销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0188","BK0239"],"gpt_icon":0},{"id":"2582498825","title":"普洛药业(000739.SZ)：盐酸文拉法辛获得化学原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582498825","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582498825?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:43","pubTimestamp":1762764221,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司全资子公司浙江普洛家园药业有限公司(以下简称“家园药业”)收到欧洲药品质量管理局(以下简称 “EDQM”)签发的盐酸文拉法辛欧洲药典适用性证书(以下简称“CEP证书”)。据悉，盐酸文拉法辛一种选择性5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)，用于治疗各种类型抑郁症(包括伴有焦虑的抑郁症)和广泛性焦虑症。本次公司盐酸文拉法辛原料药获得CEP证书，显示欧洲规范市场对该原料药质量的认可和肯定，标志着该产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000739","BK0060","CEP","BK0188","BK0239"],"gpt_icon":0},{"id":"2581091462","title":"普洛药业（000739）披露签署战略合作框架协议，11月06日股价上涨0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091462","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091462?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:17","pubTimestamp":1762438639,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，普洛药业报收于15.14元，较前一交易日上涨0.33%，最新总市值为175.39亿元。公司近日发布公告称，普洛药业股份有限公司与嘉兴安帝康生物科技有限公司近日签署《战略合作框架协议》，双方将在创新药原料药及中间体研发与外包定制生产领域建立长期战略合作关系。安帝康生物将优先委托普洛药业进行CDMO项目的研发和生产，普洛药业将提供专业CDMO服务并严格遵守技术保密要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000739","BK0060","BK0188"],"gpt_icon":0},{"id":"2581508065","title":"普洛药业最新公告：与嘉兴安帝康生物科技签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2581508065","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581508065?lang=zh_cn&edition=full","pubTime":"2025-11-06 18:51","pubTimestamp":1762426288,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司与嘉兴安帝康生物科技签署《战略合作框架协议》，双方基于战略合作关系寻求在创新药物方向更多长期合作项目，共同打造行业竞争力，不断提升药物市场竞争优势和稳定供应能力。合作内容包括安帝康生物优先选择公司进行CDMO项目的研发和生产工作，公司为安帝康生物提供专业的CDMO服务；安帝康生物优先委托公司进行CDMO项目的研发和生产，并基于项目协议之约定许可公司使用安帝康生物提供的工艺和技术。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600032064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159837","BK0188","BK0060","000739"],"gpt_icon":0},{"id":"2580673180","title":"普洛药业：公司会在回购期限内如期完成本次回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2580673180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580673180?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:49","pubTimestamp":1762260578,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好，贵公司的回购股份何时可以完成！尽快完成应该可以给广大股民增加对公司的投资信心会大大增强！谢谢！普洛药业回复：投资者您好！公司2025年股份回购方案的期限为自公司董事会审议通过回购股份方案之日起12个月内，公司会在回购期限内如期完成本次回购，请投资者关注公司股份回购进展公告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400037033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","000739"],"gpt_icon":0},{"id":"2580272209","title":"普洛药业：公司拥有奥司他韦、金刚烷胺、头孢系列等多种可用于治疗流感的药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2580272209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580272209?lang=zh_cn&edition=full","pubTime":"2025-11-04 11:37","pubTimestamp":1762227468,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：流感来袭，特别是新型甲流。请问公司直接生产抗流感药物吗，比如奥司他韦，玛舒拉沙韦，玛巴洛沙韦等，或者生产这些药品的原料药？普洛药业回复：投资者您好！公司拥有奥司他韦、金刚烷胺、头孢系列等多种可用于治疗流感的药品。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400014892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0060","BK0188","BK0239"],"gpt_icon":0},{"id":"2580298295","title":"普洛药业(000739.SZ)累计回购1006万股 耗资1.44亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580298295","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580298295?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:37","pubTimestamp":1762162657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)公告，公司截至2025年10月31日以集中竞价交易方式累计回购公司股份1006万股，占公司目前总股本的0.87%，成交总金额为1.44亿元(不含交易费用)。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)累计回购1006万股 耗资1.44亿元","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK0239","BK0060","000739"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765987301006,"stockEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":0.021},{"period":"3month","weight":-0.0249},{"period":"6month","weight":0.175},{"period":"1year","weight":0.0456},{"period":"ytd","weight":0.0347}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普洛药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41333人(较上一季度减少19.66%)","perCapita":"28016股","listingDate":"1997-05-09","address":"浙江省金华市东阳市横店江南路399号","registeredCapital":"115844万元","survey":" 普洛药业股份有限公司的主营业务是原料药中间体、创新药研发生产服务（CDMO）、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是头孢系列、青霉素系列、精神类系列、心脑血管类系列、兽药原料药中间体系列、研发服务、商业化人用药项目、商业化兽药项目、其他项目、抗感染类、心脑血管类、精神类、抗肿瘤类。","listedPrice":5.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普洛药业,000739,普洛药业股票,普洛药业股票老虎,普洛药业股票老虎国际,普洛药业行情,普洛药业股票行情,普洛药业股价,普洛药业股市,普洛药业股票价格,普洛药业股票交易,普洛药业股票购买,普洛药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}